Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Seda Kahraman, Enes Erul, Mustafa Seyyar, Özge Gümüşay, Ertuğrul Bayram, Burçin Çakan Demirel, Ömer Acar, Sercan Aksoy, Naziyet Köse Baytemür, Elif Şahin, Devrim Çabuk, Gül Başaran, Semra Paydaş, Arzu Yaren, Deniz Can Güven, Atike Pınar Erdoğan, Umut Demırcı, Alper Yaşar, İbrahim Vedat Bayoğlu, Mutlu Hızal, Burcu Gülbağcı, Nail Paksoy, Sena Ece Davarcı, Funda Yılmaz, Özlem Doğan, Sibel Oyucu Orhan, Erkan Kayıkçıoğlu, Ali Aytac, Merve Keskinkılıç, Eda Eylemer Mocan, Olçun Ümit Ünal, Esra Aydın, Hakan Yucel, Deniz Işık, Önder Eren, Başak Oyan Uluç, Melike Özçelik, İlhan Hacıbekiroğlu, Adnan Aydıner, Hacer Demir, Berna Öksüzoğlu, Ebru Cilbir, Erdem Çubukçu, Bülent Çetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgün Yıldırım, Ali Alkan, Fatih Selçukbırıcık, Asude Aksoy, Yusuf Karakaş, Gülhan Özkanlı, Berna Bozkurt Duman, Dinçer Aydın, Özgecan Dülgar, Muhammed Muhiddin Er, Fatih Teker, Tuğba Yavuzşen, Musa Barış Aykan, Ali İnal, Yakup İriağaç, Nurhan Önal Kalkan, Murat Keser, Teoman Şakalar, Serkan Menekşe, Engin Kut, Burak Bi̇lgi̇n, Müge Karaoğlanoğlu, Veli Sunar, Özlem Özdemir, Nazım Serdar Turhal, Nuri Karadurmuş, Bülent Yalçın, Mehmet Alı Nahıt Şendur
Abstract
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.